Compare
Immix Biopharma, Inc. vs Aytu Biopharma, Inc vs Celularity Inc vs Karyopharm Therapeutics Inc.
| Latest fiscal year | Immix Biopharma, Inc. IMMX | Aytu Biopharma, Inc AYTU | Celularity Inc CELU | Karyopharm Therapeutics Inc. KPTI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $57.57M | $26.55M | $146.07M |
| Revenue growth (YoY) | n/a | -13.3% | -51.0% | +0.6% |
| Gross margin | n/a | 64.0% | 24.4% (computed) | n/a |
| Operating margin | n/a | -14.4% | -230.9% | -62.1% |
| Net margin | n/a | -24.8% | -345.4% | -134.2% |
| Net income | -$29.44M | -$14.25M | -$91.72M | -$196.04M |
| EPS (Diluted) | -$0.89 | n/a | -$3.59 | -$17.93 |
| Operating cash flow | -$23.93M | $3.28M | -$13.25M | -$75.37M |
| Free cash flow | -$24.66M | $3.25M | n/a | -$75.37M |
| Cash & equivalents | $93.93M | $26.31M | $6.17M | $60.54M |
| Total assets | $104.84M | $105.01M | $107.33M | $108.42M |
| Total liabilities | $11.04M | n/a | $145.39M | $401.34M |
| Shareholders' equity | $93.80M | $35.27M | -$38.06M | -$292.93M |
| Return on year-end equity | -31.4% | -40.4% | n/a | n/a |
| Shares outstanding | 52.95M | 10.73M | 28.84M | 18.31M |
Revenue, most recent five fiscal years
| Fiscal year | Immix Biopharma, Inc. | Aytu Biopharma, Inc | Celularity Inc | Karyopharm Therapeutics Inc. |
|---|---|---|---|---|
| Latest | n/a | $57.57M Ended 2026-06-30 | $26.55M Ended 2025-12-31 | $146.07M Ended 2025-12-31 |
| 1 year earlier | n/a | $66.38M Ended 2025-06-30 | $54.22M Ended 2024-12-31 | $145.24M Ended 2024-12-31 |
| 2 years earlier | n/a | $65.18M Ended 2024-06-30 | $22.77M Ended 2023-12-31 | $146.03M Ended 2023-12-31 |
| 3 years earlier | n/a | $107.40M Ended 2023-06-30 | $17.98M Ended 2022-12-31 | $157.07M Ended 2022-12-31 |
| 4 years earlier | n/a | $96.67M Ended 2022-06-30 | $21.34M Ended 2021-12-31 | $209.82M Ended 2021-12-31 |